News

Since 2016, Autobio has been developing in the field of clinical chemistry. It currently has 190 clinical chemistry products and a number of high-end clinical chemistry analyzers, covering 12 major disease, including liver disease, kidney disease, cardiovascular disease, etc. Taking the opportunity of the release of strategic clinical chemistry products in China, the CAIVD (China Association of In-Vitro Diagnostics) interviewed Mr. Zhang Ruifeng, the leader of 2023, deputy general manager and strategic director of Autobio.

Zhang Ruifeng graduated in 1998. That year, Zhang Ruifeng met Autobio through a on-campus job fair. After listening to Chairman Mr. Miao Yongjun's grand vision for China's biopharmaceutical industry and the Autobio's development blueprint, Zhang Ruifeng was deeply inspired and joined Autobio without hesitation. He chose to start from front-line sales and was determined to move forward with Autobio.

After 26 years of hard work, Autobio has leapt from a small company to the first echelon of China's in vitro diagnostic companies. Its products cover multiple fields such as immunoassay, microbiology, clinical chemistry, molecular, coagulation, and have made forward-looking layouts in precision detection fields such as sequencing and mass spectrometry. Zhang Ruifeng has also been promoted with the development of the company, growing from a young man to the deputy general manager and strategic director of Autobio. This resume is not only a valuable asset in his career, but also a permanent feeling and pride in his heart. He firmly believes that there must be great strategic support behind a great company. In his view, the strategy of a company is a bridge connecting the current situation with future goals. Through carefully formulated strategic planning, a company can accurately grasp the development trends of the industry in the external environment, and make appropriate adjustments internally according to its own development, thereby continuously enhancing the company's core competitiveness.

Mr. Zhang Ruifeng said that strategic planning is a specific arrangement of the stage development goals that the company must achieve in a certain period of time in the future. It not only enables employees at all levels to clarify the common goals of the company, enhance the cohesion and centripetal force of the company, but also enables everyone to clearly understand the company's work priorities and resource needs at different stages. In this way, the design of organizational structure and the integration of resources can be more purposeful and principled, ensuring the optimization of resource allocation and laying a solid foundation for the development of the company.

Following the rapid development of the company, Zhang Ruifeng witnessed the birth of a series of iconic products:

The successful development of a series of innovative products is due to the company's continuous R&D investment and strong innovation capabilities for many years. Autobio has always put technological innovation at the top of its strategy and regarded continuous R&D and innovation capabilities as an important means to enhance the company's core competitiveness. According to Mr. Zhang Ruifeng, for many consecutive years, the company's R&D investment has accounted for more than 12% of its revenue. In 2023, the R&D investment was RMB 656 million, accounting for 14.77% of its operating income, which is higher than the average level of the same industry. In addition, Autobio continues to absorb outstanding innovative talents. At present, the company's R&D team has more than 1,800 people, accounting for about 30% of the total number of employees, and is one of the companies with more R&D personnel in the industry.

The establishment of Autobio's R&D system is not only reflected in the investment of human and financial resources. In order to make the R&D structure layout more perfect, it has formed a R&D system with Zhengzhou as the center and Beijing, Shanghai, Suzhou, Shenzhen and the United States as auxiliary branches. It makes full use of the talents and technical advantages of various places, forms a high-quality R&D team, and enters the frontier technologies and products development in the IVD field. After more than ten years of raw material research and development , Autobio has created a diagnostic antibody library for tens of thousands of antigen epitopes. The raw materials of immunoassay products are basically self-sufficient, ensuring the stability and safety of supply.

Faced with the growing demand for diversified and personalized medical services, the demand for TLA is also growing. In the interview, Mr. Zhang Ruifeng specifically mentioned that since the launch of the first TLA in 2017, Autobio has won wide acclaim in the market with its high-quality products and innovative solutions. In addition, AutoLas X-1 won the "Oscar" of the design industry-the 2023 iF Award, which reflects the high recognition of Autobio's innovation and manufacturing capabilities in the international industrial design field. In terms of appearance design, AutoLas X-1 incorporates a variety of natural ecological elements. The transparent cover is like a slowly flowing river, closely connected with the module shaped like a lake, together forming a harmonious "ecological water system". The undulating module shape is more like a quiet "landscape painting", bringing a touch of tranquility and harmony to the busy laboratory. The design concept of "simplifying the complex" allows AutoLas X-1 to realize the automation of the detection process, greatly improving the accuracy and timeliness of the test, and also reducing the workload of the laboratory.

"In addition to the eye-catching appearance design, from the customer's perspective, when choosing an TLA, factors such as the richness and stability of the reagents are crucial. Only by ensuring the stability of the reagent quality can the TLA be guaranteed to perform at its best." Mr. Zhang Ruifeng said. At present, Autobio has 158 immunoassay reagents and 125 clinical chemistry reagents in China. Looking forward to the future, the total number of reagents will reach more than 500, making it one of the companies with the most complete reagents in China.

The R&D and production of medical instrument is a thorny road. Every technological innovation is accompanied by countless days and nights of hard work. From the bright lights of the laboratory to the roar of the production line, every detail embodies the hard work and sweat of the team. The team knows that in order to stand out in the fierce market competition, it is necessary to adhere to high standards and strict requirements. The company must not only have strong R&D capabilities, but also have an indomitable heart.

In the process of business operation, Mr. Zhang Ruifeng believes that true success is not only the expansion of market share, but also the recognition of social contribution. While achieving results, actively participate in public welfare, give back to the society, and demonstrate corporate responsibility. For 26 years, Autobio has been down-to-earth, supported by faith, and escorted life. The persistent pursuit of quality and social responsibility has established a good reputation for the company. It will continue to be committed to the promotion and advancement of medical laboratory technology, dedicated to serving human healthcare. While paying attention to indicators such as detection performance and stability, it also focus on product design and operating experience, and strives to provide medical laboratories with more and better products and services to better serve human healthcare.